CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.59BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.42xvs all stocks
52-Week Change
612.96%vs all stocks
Market Capitalization
2.59BUSDvs all stocks (USD)
Enterprise Value
2.08BUSDvs all stocks (USD)
Forward P/E
-94.00xvs Biotechnology peers
Price to Book (MRQ)
19.85xvs Biotechnology peers
Enterprise to EBITDA
-73.55xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.45%vs Biotechnology peers
Return on Equity (TTM)
-43.59%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-29.46MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-28.16MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-17.66MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-28.27MUSDvs all stocks (USD)
Pre-tax Income
-26.86MUSDFY2025 · Dec 31, 2025Net Income
-26.86MUSDFY2025 · Dec 31, 2025EBIT
-28.27MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-28.27MUSDFY2025 · Dec 31, 2025Research & Development
16.02MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
12.25MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.41MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2500USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
109.05MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
109.05MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-26.86MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-25.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
71.89MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-26.86MUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
597.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-535.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-635.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-527.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
22.52MUSDFY2025 · Dec 31, 2025Shares Outstanding
181.33MSharesUpdated Jul 19, 2026Shares Short
63.31MSharesUpdated Jul 19, 2026Short Ratio
6.31daysvs all stocks
Short % of Shares Outstanding
32.33%vs all stocks
% Held by Insiders
0.95%vs all stocks
% Held by Institutions
27.84%vs all stocks
Total Cash (MRQ)
107.10MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5760USDUpdated Jul 19, 2026Total Debt (MRQ)
871.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0081xvs Biotechnology peers
Current Ratio (MRQ)
17.22xvs Biotechnology peers
Book Value per Share (MRQ)
0.5920USDUpdated Jul 19, 2026Total Assets
78.34MUSDvs all stocks (USD)
Total Current Assets
75.21MUSDFY2025 · Dec 31, 2025Total Liabilities
7.47MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.13MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
457.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
71.79MUSDFY2025 · Dec 31, 2025Accounts Payable
2.95MUSDFY2025 · Dec 31, 2025Short-term Debt
544.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
42.00KUSDFY2025 · Dec 31, 2025Long-term Debt
457.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-274.99MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
70.87MUSDvs all stocks (USD)
52-Week Low
1.39USDUpdated Jul 19, 202652-Week High
15.88USDUpdated Jul 19, 202652-Week Change
612.96%vs all stocks
Beta
2.42xvs all stocks
50-Day MA
9.29USDUpdated Jul 19, 2026200-Day MA
4.87USDUpdated Jul 19, 2026Avg 10-Day Volume
9.09MSharesUpdated Jul 19, 2026Avg 30-Day Volume
9.87MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.2300USDUpdated Jul 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.59B, above the global median of $1.15BNotable
Market cap (USD): 2,593,583,651Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Immunovant Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Peric Special Gases Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Hebei Sinopack Electronic Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets